ログイン/ 登録

だいたい ACP

Arena Competition Protocol (aof.global) (ACP) は 2026 に発売された暗号通貨です。 ACP には現在 1.00Bn の供給量があり、0 が流通しています。 ACP の最後に知られている価格は 0.005082943601 米ドルで、過去 24 時間の価格は 0.000171151287 です。現在、 個のアクティブな市場で取引されており、過去 24 時間に $222,329.03 個が取引されました。詳細については、 をご覧ください。
ACP 価格統計
ACP 今日の価格
24時間価格変更
+$0.0001711512873.48%
24h取引量
$222,329.0338.42%
24 時間低/24 時間高
$0 / $0
取引高/時価総額
--
市場支配力
0.00%
市場ランク
#4171
ACP 時価総額
時価総額
$0
完全希薄化時価総額
$5.08M
ACP 価格履歴
7 日低/7 日高
$0 / $0
過去最高
$0
過去最低
$0
ACP供給
循環供給
0
総供給量
1.00Bn
最大供給量
1.00Bn
更新しました 7月 24, 2026 9:51 午前
image
ACP
Arena Competition Protocol (aof.global)
$0.005082943601
$0.000171151287(+3.48%)
MCap $0
ここには何もありません。
Mingyu Pharma Refiles for Hong Kong Listing as Priority Share Liabilities Reach 2.81 Billion Yuan
Mingyu Pharma Refiles for Hong Kong Listing as Priority Share Liabilities Reach 2.81 Billion Yuan
Mingyu Pharma has refiled for a Hong Kong listing after its first application lapsed, seeking to return to the city’s Chapter 18A biotech route, according to Jiemian News. The company is led by founder Cao Guoqing, a former Eli Lilly and Hengrui Medicine scientist, and is developing a TROP-2 ADC, a PD-1/VEGF bispecific antibody and an external JAK inhibitor. In oncology, Mingyu’s main combination strategy pairs its TROP-2 ADC MHB036C with the PD-1/VEGF bispecific MHB039A. The company said MHB036C showed anti-tumor activity at low doses without major hematologic toxicity, with interstitial lung disease incidence of about 1%. MHB039A is in Phase II development, while the combination is being tested in China in non-small cell lung cancer in Phase I/II and breast cancer in Phase II. In autoimmune disease, Mingyu’s external JAK inhibitor MH004 targets mild to moderate atopic dermatitis in adolescents and adults, and is also being developed for vitiligo. Its new drug application was accepted by China's National Medical Products Administration in May 2025, refiled after supplemental materials in March 2026, and accepted again in April 2026. The company expects potential approval in the first half of 2027. Mingyu also disclosed a heavy liability burden. As of May 31, 2026, the fair value of its preferred shares stood at 2.81 billion yuan, or 98.3% of total liabilities, while cash and cash equivalents were 605 million yuan, down from 801 million yuan at the end of 2025. The company said it has raised about $240 million through five rounds of convertible preferred-share financing since its founding in 2018. In March 2025, Mingyu signed an exclusive licensing deal with Qilu Pharmaceutical for MHB088C in Greater China worth up to 1.345 billion yuan, including 280 million yuan upfront and up to 1.065 billion yuan in milestones. It booked 264 million yuan in revenue in 2025 from the deal, but had no new licensing income in the first five months of 2026 and reported a net loss of 1.3 billion yuan from 2024 through the first five months of 2026.
7月 24, 2026 9:52 午前
China, ASEAN Call for De-Escalation in Middle East and Deeper Energy Cooperation
China, ASEAN Call for De-Escalation in Middle East and Deeper Energy Cooperation
China and ASEAN foreign ministers issued a joint statement on July 24 on the impact of Middle East developments on the region and on strengthening regional energy cooperation. The statement, released on China's Foreign Ministry website and covering a meeting held in Manila on July 22, called for diplomacy, restraint and an immediate halt to hostilities on all fronts in the Middle East, according to Jiemian News. The ministers welcomed ongoing diplomatic contacts, including talks between the United States and Iran mediated by Pakistan and Qatar, and urged all parties to respect sovereignty, territorial integrity and ceasefire terms, while protecting civilians, civilian infrastructure and humanitarian access. They also reaffirmed support for freedom of navigation under international law and, under the 1982 U.N. Convention on the Law of the Sea, called for safe and uninterrupted transit through international straits. On energy, China and ASEAN agreed to explore a cooperation mechanism for policy exchanges and practical cooperation, strengthen regional energy security and resilience, and expand work on power-grid connectivity, supply chains, clean and renewable energy, energy technology innovation and civilian nuclear power. The statement also backed the ASEAN Energy Cooperation Action Plan (2026-2030) and said both sides would look for financing support from ASEAN bodies, multilateral development banks, international financial institutions and the China-ASEAN Investment Cooperation Fund.
7月 24, 2026 9:52 午前

よくある質問

  • Arena Competition Protocol (aof.global) (ACP)の史上最高価格はいくらですか?

    ACPの史上最高値は 0 米ドルで、1970-01-01 に記録されています。現在のコイン価格は最高値から 0% 下落しています。 (ACP)の史上最高価格は 0 米ドルです。現在の価格は史上最高値から 0% 下落しています。

    続きを読む
  • Arena Competition Protocol (aof.global) (ACP)の流通量はいくらですか?

    2026-07-24現在、流通中の ACP の量は 0 です。 ACP の最大供給量は 1.00Bn です。

    続きを読む
  • Arena Competition Protocol (aof.global) (ACP)の時価総額はいくらですか?

    ACPの現在の時価総額は 0 です。これは現在の ACP の供給量にそのリアルタイムの市場価格 0.005082943601 を掛けて計算されます。

    続きを読む
  • Arena Competition Protocol (aof.global) (ACP)の史上最低価格はいくらですか?

    ACPの史上最低値は 0 で、1970-01-01 に記録されています。現在のコイン価格は史上最低値から 0% 上昇しています。 (ACP)の史上最低価格は 0 米ドルです。現在の価格は史上最低値から 0% 上昇しています。

    続きを読む
  • Arena Competition Protocol (aof.global) (ACP) は良い投資ですか?

    Arena Competition Protocol (aof.global) (ACP) の時価総額は $0 で、CoinMarketCap では #4171 にランクされています。暗号通貨市場は非常に変動しやすいため、必ず自分で調査 (DYOR) を行い、リスク許容度を評価してください。さらに、Arena Competition Protocol (aof.global) (ACP) の価格傾向とパターンを分析して、ACP を購入する最適な時期を見つけます。

    続きを読む